IGC Pharma
25 hedge funds and large institutions have $691K invested in IGC Pharma in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 7 closing their positions.
517% more call options, than puts
Call options by funds: $37K | Put options by funds: $6K
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
1.37% less ownership
Funds ownership: 5.24% → 3.87% (-1.4%)
7% less funds holding
Funds holding: 27 → 25 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
32% less capital invested
Capital invested by funds: $1.01M → $691K (-$322K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6.92K |
| 2 |
JP Morgan Chase
New York
|
+$1.52K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.38K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$614 |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$48 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$59K |
| 2 |
Renaissance Technologies
New York
|
-$31K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$17.2K |
| 4 |
Jane Street
New York
|
-$16.7K |
| 5 |
HF
HRT Financial
New York
|
-$6K |
IGC Hedge Fund Activity: Q4 2023 in Review
25 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q4 2023, worth a combined $691K — down 32% from $1.01M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of IGC and 5 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 5 added.
The largest buyer was Susquehanna International Group, adding an estimated $6.92K. The largest seller was Commonwealth Equity Services, exiting entirely with an estimated $59K sold.
- 25 institutional investors held IGC Pharma (IGC) as of Q4 2023, down from 27 in Q3 2023.
- Funds reported $691K of IGC Pharma stock for Q4 2023, down 32% quarter-over-quarter.
- 5 funds opened new IGC Pharma positions in Q4 2023 and 7 closed out, a net change of -2 holders.
- The largest IGC Pharma buyer in Q4 2023 was Susquehanna International Group, an estimated $6.92K added.
- The largest IGC Pharma seller in Q4 2023 was Commonwealth Equity Services, an estimated $59K sold.
Based on aggregated 13F filings for Q4 2023.